(S)-N-Boc-2,2-二甲基噁唑烷-4-甲酸 | 139009-66-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-N-Boc-2,2-二甲基噁唑烷-4-甲酸
• 中文别名: (S)-3-(叔丁氧基羰基)-2,2-二甲基噁唑啉-4-羧酸；S-3-Boc-2,2-二甲基恶唑烷-4-甲酸
• 英文名称: (S)-3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid
• 英文别名: (4S)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid；(4S)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-oxazolidine-4-carboxylic acid
• CAS: 139009-66-8
• 化学式: C₁₁H₁₉NO₅
• 分子量: 245.276
• InChiKey: XUYBSTJQGVZMSK-ZETCQYMHSA-N

物化性质

• 沸点：
  358.2±42.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境中保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-3-(tert-Butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-3-(tert-Butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid
CAS number: 139009-66-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H19NO5
Molecular weight: 245.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-N-Boc-2,2-二甲基噁唑烷-4-甲酸 在 吗啉 、 sodium tetrahydroborate 、 tris(triphenylphosphano)palladium 、 N,N'-羰基二咪唑 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 六甲基磷酰三胺 为溶剂， 反应 6.0h， 生成 (2S,3R)-2-[(tert-butoxycarbonyl)amino]-1,2-O-N-isopropylideneoctadecane-1,3-diol
  参考文献：
  名称：

  Synthesis of D-erythro-sphingosine and D-erythro-sphinganine via 3-ketosphinganine

  摘要：

  D-erythro-sphingosine and D-erythro-sphinganine can be produced in protected form from serine by a synthetic approach in which the normal biological intermediate 3-ketosphinganine in protectyed form, is a key synthetic intermediate. The sequence is short and convergent, proceeds in goad overall yields (approximate to 30% for 6 steps) and with excellent stereocontrol (>91% de, >95% ee). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)00733-3
• 作为产物：
  描述：

  Boc-L-丝氨酸甲酯 在 三氟化硼乙醚 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 丙酮 为溶剂， 反应 5.0h， 生成 (S)-N-Boc-2,2-二甲基噁唑烷-4-甲酸
  参考文献：
  名称：

  在 NosN 催化的反应中捕获中间体，NosN 是一种参与那西肽侧环系统生物合成的 C 类自由基 S-腺苷甲硫氨酸甲基化酶

  摘要：

  那西肽是一种核糖体合成和翻译后修饰的硫肽天然产物，具有抗菌、抗癌和免疫抑制特性。它包含一个双环结构，由一个大环和一个独特的侧环系统组成，该系统包含一个 3,4-二甲基吲哚酸桥，分别通过酯键和硫酯键连接到核心肽的 Glu6 和 Cys8 的侧链。除了由 nosM 基因编码的结构肽外，侧环结构的生物合成还需要 NosI、-J、-K、-L 和 -N 的作用。NosN 被注释为 C 类自由基 S-腺苷甲硫氨酸 (SAM) 甲基化酶，但它的真正功能是将 C1 单元从 SAM 转移到 3-甲基-2-吲哚酸 (MIA) 的 C4 上，同时在核心肽的 Glu6 羧酸盐和新生的 C1 单元之间形成键。然而，在那西肽的生物合成过程中，NosN 究竟何时发挥其功能尚不清楚。在此，我们报告了三种肽模拟物作为潜在底物的合成和使用，旨在解决 NosN 功能的时间问题。我们的结果表明，NosN 在 NosO 形成吡啶环之前清楚地关闭了侧环，最有可能在

  DOI：

  10.1021/jacs.8b13157
• 作为试剂：
  描述：

  在 1-丙基磷酸酐 、 三乙胺 、 (S)-N-Boc-2,2-二甲基噁唑烷-4-甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide
  参考文献：
  名称：

  WO2013/84150

  摘要：

  公开号：

文献信息

• Kinetic deconjugation: a gateway to the synthesis of Xxx-Gly (E)-alkene dipeptide isosteres
  作者：Arnaud Proteau-Gagné、Jean-François Nadon、Sylvain Bernard、Brigitte Guérin、Louis Gendron、Yves L. Dory

  DOI：10.1016/j.tetlet.2011.09.136

  日期：2011.12

  A new method for the preparation of Xxx-Gly (E)-alkene dipeptide isosteres (EADIs), using LDA deprotonation followed by 1 N HCl quench, was explored. The method, named kinetic deconjugation, enabled the synthesis of Tyr-Gly, Gly-Gly, Ser-Gly, Pro-Gly, and Phe-Gly EADIs, as well as one Tyr-Gly trisubstituted alkene dipeptide isostere (TADI). Overall, this method, based on commercially available materials

  探索了一种新的制备Xxx-Gly（E）-烯烃二肽等排物（EADIs）的方法，该方法使用LDA脱质子化，然后用1 N HCl淬灭。该方法称为动力学解偶联，能够合成Tyr-Gly，Gly-Gly，Ser-Gly，Pro-Gly和Phe-Gly EADIs，以及一种Tyr-Gly三取代烯烃二肽等排物（TADI）。总体而言，该方法基于可商购的材料，可实现高收率，仅需很少的合成步骤，并且可以在多种EADI的合成中达到克级。
• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• [EN] PIPERAZINE DERIVATIVE RENIN INHIBITORS<br/>[FR] DERIVES DE PIPERAZINE AGISSANT COMME INHIBITEURS DE LA RENINE
  申请人：WARNER LAMBERT CO

  公开号：WO2004089915A1

  公开（公告）日：2004-10-21

  Disclosed are piperazine derivatives, their manufacture and use as inhibitors of renin. Formula (I):

  揭示了哌嗪衍生物，它们的制备以及作为肾素抑制剂的用途。化学式（I）：
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：NOVARTIS AG

  公开号：US20200164024A1

  公开（公告）日：2020-05-28

  The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , X 1 , X 2 , and X 3 are described herein.

  该披露涉及对PCSK9的抑制剂，用于治疗胆固醇脂质代谢以及其他PCSK9发挥作用的疾病，其化学式为(I)： 或其药用可接受的盐、水合物、溶剂合物、前药、立体异构体、N-氧化物或互变异构体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和X3如本文所述。